Formycon says it has now received a target action date in next June from the US Food and Drug Administration for its FYB203 proposed biosimilar rival to Eylea (aflibercept), which is due to be marketed in the US by Coherus Biosciences.
Formycon Gets Date For Aflibercept Filing In US
US FDA Offers June 2024 Action Date For Coherus-Partnered FYB203 Eylea Biosimilar
Formycon has announced a June 2024 FDA action date for its FYB203 proposed aflibercept biosimilar rival to Eylea, which is due to be marketed by Coherus in the US.

More from Biosimilars
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
Four key areas for policy reform were identified by industry association Medicines for Europe at its biosimilars conference in early April, as sector chair Isabell Remus set out the importance of removing barriers to biosimilar competition.
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.